Pyxis Oncology 2025 net loss widens on higher R&D spend

Pyxis Oncology

23/03/2026 11:09

Overview

US biopharmaceutical developer's 2025 revenue fell yr/yr, net loss widened

Company completed target enrollment in MICVO Phase 1 monotherapy study for head and neck cancer

Pyxis Oncology expects cash runway into fourth quarter of 2026

Outlook

Pyxis Oncology expects cash runway into the fourth quarter of 2026

Result Drivers

REVENUE SOURCES - 2025 revenue driven by regulatory milestone for suvemcitug approval in China and sale of royalty rights for Enzeshu

R&D SPENDING - Higher research and development expenses due to increased contract manufacturing and clinical trial costs for MICVO

COST REDUCTION - Lower general and administrative expenses mainly from reduced employee-related costs, insurance, and professional fees

Company press release: ID:nGNX6k2FkC

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-$1.28
FY Net Income
-$79.62 mln
FY Basic EPS
-$1.28
FY Income from Operations
-$84.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Pyxis Oncology Inc is $7.00, about 376.2% above its March 20 closing price of $1.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)